e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Non-exhaled biomarkers in the assessment of airways disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum levels of RAAS components in COPD
Ümran Toru (Kütahya, Turkey), Ümran Toru, Ceylan Ayada, Osman Genç, Server Sahin, Özlem Arik, Ismet Bulut
Source:
International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Session:
Non-exhaled biomarkers in the assessment of airways disease
Session type:
Thematic Poster Session
Number:
3970
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ümran Toru (Kütahya, Turkey), Ümran Toru, Ceylan Ayada, Osman Genç, Server Sahin, Özlem Arik, Ismet Bulut. Serum levels of RAAS components in COPD. Eur Respir J 2015; 46: Suppl. 59, 3970
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Serum levels of leptin and visfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Different data in COPD
Year: 2015
Increased serum level of apelin in chronic obstructive pulmonary disease
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Production of proinflammation cytokines and mean pulmonary arterial pressure in COPD
Source: Annual Congress 2013 –The vulnerable patient and ageing cells
Year: 2013
Increased total serum levels of ghrelin and nesfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
microRNA profile in COPD patients with and without pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
The prevalence and characteristics of pulmonary hypertension in severe COPD
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Pulmonary hypertension and COPD: Clinical assessment and biomarkers
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013
Evidence of renal and pulmonary endothelial dysfunction in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015
Hypoxia associated with increased systemic concentrations of MPO and NE during exacerbations of COPD
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015
Dysregulation of serum miRNA in chronic obstructive pulmonary disease
Source: International Congress 2015 – Genetics, genomics and exposures in asthma and COPD
Year: 2015
Pulmonary vessels remodeling in COPD
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
TNF-α, IL-6, IL-10 serum activity in patients with obesity-associated arterial hypertension depend on bronchial obstruction presence
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive lung disease?
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Increased heart rate modulation, sympathetic dominance and systemic inflammation in chronic obstructive pulmonary disease
Source: International Congress 2014 – Markers
Year: 2014
Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013
Plasma levels of TIPM-2 in patients with COPD
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
Dynamics of sputum antimicrobial peptide levels in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015
Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept